Pedro Valencia, VP, asset strategy leadership, oncology, AbbVie, discusses how early data from ABBV-706 shows up to 50% ...

A young university student whose repeated symptoms of stomachache, nausea, vomiting, and weight loss were dismissed by ...

Zanzalintinib plus Tecentriq significantly improved overall survival versus Stivarga in previously treated metastatic ...

Pedro Valencia, VP, asset strategy leadership, oncology, outlines how unmet need, treatment stagnation, and pipeline innovation shape the company’s approach to solid tumor oncology following key data ...

If approved, Cabometyx® would be the first and only systemic therapy approved in the European Union for previously treated ...

Companies like AstraZeneca, Daiichi Sankyo, Pfizer and Merck are learning from previous setbacks in the ADC space to improve ...

More people under 50 are getting appendix cancer. Here's what to know about this type of cancer, as well as why case rates ...